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One of the most difficult decisions a woman can be faced with when choosing breast 
cancer treatment is whether or not to undergo breast conserving surgery or mastectomy. 
The factors that influence these treatment decisions are complex and involve issues 
regarding access to health care, concerns for cancer recurrence, and the impact of 
surgery on body image and sexuality. Understanding these factors will help practitioners 
to improve patient education and to better guide patients through this decision-making  
process. Although significant scientific and societal advances have been made in 
improving women’s choices for the breast cancer treatment, there are still deficits in the 
decision-making processes surrounding the surgical treatment of breast cancer. Further 
research is needed to define optimal patient education and shared decision-making 
practices in this area.
Keywords: mastectomy, breast cancer, breast conserving surgery, shared decision-making, contralateral 
prophylactic mastectomy
iNTRODUCTiON
Medical decision-making has evolved over the last several decades from one based on paternalism, 
in which the physician decided on the best course of treatment according to his/her view of what 
was in the best interest of the patient, to one focused on patient autonomy, in which the informed 
patient makes decisions about accepting or declining treatment options based on his/her own 
values and priorities. In modern medical ethics, shared decision-making has been proposed as 
the ideal model for medical decision-making that both acknowledges patient autonomy and the 
role of the physician in providing expert medial opinion. Shared decision-making is a process that 
informs patients about what available treatments are most effective under particular circumstances, 
incorporates patients’ needs and values into decisions, and improves the patient–clinician dialog 
about decisions (1, 2). Shared decision-making has been advocated as an ideal model to address 
treatment decisions in which no single treatment option is clearly indicated above others based on 
available medical evidence (2). Therefore, this model is particularly suited to treatment decisions 
in the management of the primary tumor in breast cancer, as a patient may face several surgical 
treatment options that result in equivalent oncologic outcomes.
One of the most difficult decisions a woman can be faced with when choosing breast cancer 
treatment is whether or not to undergo breast conserving surgery (BCS) or mastectomy. Notably, the 
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clinical research in breast cancer treatment, which supports the 
use of BCS, came about at the time when women were also becom-
ing dissatisfied with the traditional paternalistic doctor–patient 
relationship model and were demanding to have more choice in 
their medical care. In his book, “The Breast Cancer Wars,” Barron 
Lerner chronicles the convergence of the women’s liberation 
movement and the rise of BCS as the standard of surgical care in 
the treatment of early stage disease (3). In 1971, the writer Babette 
Rosamond was diagnosed with breast cancer when one of the 
first proponents of BCS, Bernard Crile, was offering a partial 
mastectomy as opposed to the traditional one-step procedure 
in which a woman with a suspicious breast mass was consented 
for an excisional biopsy under anesthesia and if this mass was 
determined to be a cancer on frozen section, the surgeon would 
then proceed with a radical mastectomy, which included the 
removal of the breast, overlying skin, axillary lymph nodes, and 
pectoralis muscles. When Babette Rosamond was presented with 
the one-step procedure, she refused and only gave permission for 
the excisional biopsy. The excision demonstrated a small focus 
of breast cancer. She then refused the radical mastectomy and 
sought out the opinion of Dr. Crile at the Cleveland Clinic who 
cited data from retrospective studies of less aggressive surgery, 
resulting in acceptable outcomes. Ms. Rosamond wrote about her 
experience in an article, “The Right to Choose,” in the popular 
woman’s journal McCall’s Magazine and ultimately published a 
book entitled, “The Invisible Worm.” She joined a host of other 
women leaders of the time who were vocal proponents against 
the current medical establishment’s support of aggressive breast 
cancer surgery who demanded choice in their cancer care and the 
option of less aggressive and more cosmetic procedures.
Concurrently, in the late 1960s, the surgeon Bernard Fisher 
developed and promoted a biological model of breast cancer 
in which he proposed that breast cancer was a systemic disease 
requiring both local and systemic treatment (4). Therefore, more 
radical surgery was not necessarily beneficial in the face of dis-
seminated tumor cells. Although commending Crile and others 
for pursuing BCS, Fisher demanded more rigorous evidence to 
support less aggressive surgery by means of randomized clinical 
trials. Under his leadership, the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) B04 and B06 trials were conducted. 
The NSABP-B04 trial demonstrated that sparing the pectoralis 
muscles in mastectomy did not negatively affect oncologic 
outcomes (5). The NSABP-B06 trial established that BCS results 
in equivalent overall survival as mastectomy in patients with 
early stage breast cancer (6). The addition of adjuvant radiation 
treatment to BCS decreased the rate of local recurrence from 39 
to 14% over 20  years. To date, there are multiple randomized 
clinical trials with long-term follow-up demonstrating no dif-
ference in overall survival between BCS with adjuvant radiation 
and mastectomy for the treatment of operable breast cancers 
(6–11). Refinement of radiation techniques and the addition of 
adjuvant systemic therapies have further decreased the rate of 
local recurrence in BCS to approach that of mastectomy (12, 13). 
Currently, one of the quality assurance standards for the National 
Accreditation Program for Breast Centers in the United States is 
that at least 50% of Stages 1–2 breast cancers amenable to BCS are 
treated with partial mastectomy.
MASTeCTOMY AND BReAST 
CONSeRvATiON
Despite data supporting BCS in eligible patients, a significant per-
centage of women who would be candidates for BCS still decide 
to undergo mastectomy. The factors that influence these treat-
ment decisions are complex and involve issues regarding access 
to health care, concerns for cancer recurrence, and the impact 
of surgery on body image and sexuality. Understanding these 
factors will help practitioners to improve patient education and 
to better guide patients through this decision-making process.
Access to health care is one of the major determinants of 
choice for breast cancer surgery, especially with regard to access 
to specialty providers and treatment facilities. Because adjuvant 
radiation therapy is usually recommended after BCS, multiple 
studies have focused on the availability of radiation oncology 
specialists. A recent publication using data from the surveillance, 
epidemiology, and end results (SEER) database and the Health 
Resources and Services Administration Area Resource File 
evaluated the association between the choice of breast surgery 
(mastectomy or BCS), the receipt of adjuvant radiation therapy 
after BCS, and the density of radiation oncologists in a particular 
area (ROD) (14). The study demonstrated that the likelihood of 
a woman undergoing BCS for early stage breast cancer increased 
as the ROD in an area increased. In addition, the likelihood that 
adjuvant radiation therapy was omitted after BCS decreased as 
the ROD in an area increased. The results from this study are 
consistent with those of a large study using the Medicare database 
that evaluated the use of BCS in older breast cancer patients and 
demonstrated that BCS was used more frequently in counties 
with a high density of radiation oncologists (15).
Numerous studies have also demonstrated that travel distance 
for radiation therapy may be associated with decisions regarding 
BCS and the actual delivery of adjuvant radiation therapy after 
BCS (16–21). The largest of these studies evaluated the use of BCS 
in women with early stage breast cancer using the SEER database 
(17). This study showed that the use of BCS was more common 
when women received treatment in a hospital with a radiation 
facility compared to women living a greater distance from a 
hospital with a radiation center. This was statistically significant 
for women who resided ≥15 miles from the nearest hospital with 
a radiation treatment center (OR 0.52, 95% CI 0.46–0.58). The 
study also demonstrated that for women who had BCS, a statisti-
cally significant decrease in the use of adjuvant radiation therapy 
was observed in patients who lived ≥40 miles from a hospital with 
a radiation facility, although this only accounted for 1.7% of the 
patients in the study. The use of accelerated radiation schedules, 
including shorter course whole breast irradiation given over 
3  weeks and partial breast irradiation, may help to ameliorate 
some of these issues by providing patients with more manageable 
radiation schedules.
The use of multidisciplinary treatment teams is becoming more 
common in the management of breast cancer patients, especially 
at larger, academic institutions where breast cancer specialists are 
available in multiple disciplines. However, a significant percent-
age of patients still do not have the opportunity to meet with a 
medical oncologist or radiation oncologist before undergoing 
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surgery for breast cancer. One of the benefits of a multidiscipli-
nary approach is that patients understand all the components of 
their breast cancer treatment prior to starting treatment, and this 
increased knowledge may have an impact on treatment decisions 
regarding surgery for breast cancer. In a study of elderly women 
aged ≥65 years with local or regional breast cancer treated from 
1994 to 1995, those patients who had a consultation with a radia-
tion oncologist preoperatively were 6.7 times more likely to have 
BCS compared to those who did not (P ≤ 0.001). Furthermore, 
the odds of a patient receiving adjuvant radiation therapy after 
BCS were five times greater for patients who had a preoperative 
radiation oncology consultation (P < 0.001). Although this study 
was conducted at the time when multidisciplinary care was not as 
prevalent as it is today, it did demonstrate how multidisciplinary 
care may influence treatment choices (22). Several studies have 
demonstrated that surgeon characteristics including practice set-
ting and gender have an impact on BCS rates (23–25). Surgeons 
who are affiliated with academic institutions, whether or not they 
have fellowship training in breast surgery or surgical oncology, 
use BCS more often than community surgeons (23). This may 
be due to the greater availability of other specialty providers at 
academic institutions and the use of multidisciplinary care in this 
setting. The number and availability of reconstructive surgeons 
at a particular institution have also been shown to impact rates 
of mastectomy and reconstruction and BCS (19). In an analysis 
of patients treated for breast cancer at National Comprehensive 
Cancer Network institutions, a greater number of reconstructive 
surgeons were associated with increased mastectomy and recon-
struction rates, whereas long wait times for breast reconstructive 
surgery were associated with increased BCS rates.
Factors predicting the use of BCS, including clinicopatho-
logic, socioeconomic, and patient characteristics, have been 
examined in numerous studies. Tumor characteristics, includ-
ing tumor size, lymph node involvement, and stage, have all 
been shown to influence treatment decisions, with BCS used 
more frequently in patients with smaller tumors (23, 26) 
without lymph node involvement (15) and mastectomy used 
more often in patients with higher stage (27). Socioeconomic 
factors, including higher education, low poverty areas, and 
private insurance, are also associated with increased use of 
BCS (15, 21, 24). Significant geographic variation also exists in 
the use of BCS, both local and regional. Multiple studies have 
demonstrated that patients living in the Northeast and Pacific 
West are more likely to have BCS than those in the South (15, 
23, 26, 28). In an analysis of older breast cancer patients, 70% 
of the patients in the Northeast had BCS compared to 48–50% 
of patients in the South (P < 0.001) (15). In this study, patients 
in metropolitan areas were also more likely to have BCS than 
patients in rural areas. This may simply reflect decreased access 
to health care and particularly breast cancer specialists. This 
geographic variation may also be influenced by other factors, 
including education and socioeconomic status.
Although some single institution studies have shown that 
younger patient age is associated with the use of BCS (15, 21, 23, 24), 
more recent analysis of large national databases suggest that this 
trend has reversed. Two reviews of the National Cancer Database 
have demonstrated in the setting of an overall increase of BCS, 
younger patients are being treated with mastectomy at higher rates 
than their older counterparts after adjusting for patient, facility, 
and tumor characteristics (28, 29). The subset of women aged 
≤35 years was twice as likely to undergo mastectomy compared to 
women aged 61–64 years (29). These studies also reported similar 
trends with socioeconomic status, geography, and cancer stage 
outlined above, with a more recent narrowing of the BCS disparity 
in the South (28). In addition, access to radiation also appeared 
to influence BCS rates in these studies. It is unclear why younger 
women may be opting for more extensive surgery. This may be due 
to a concern for locoregional recurrence in younger patients (30), 
although more aggressive surgery does not appear to affect breast 
cancer-specific survival (31). Increased awareness of familial 
breast cancer syndromes may also be affecting mastectomy rates 
in younger women, who are at higher risk for having a deleterious 
genetic mutation and therefore may be choosing bilateral mastec-
tomy for the treatment of a unilateral cancer.
When patients are diagnosed with breast cancer, they obtain 
support and advice from multiple sources when making deci-
sions regarding breast surgery. The surgeon’s recommendation or 
preference for care is frequently cited as an important factor in 
this decision-making process. In a survey study that examined 
breast cancer care in a group of 96 patients, women who chose 
BCS indicated that the most important factor in the decision was 
the surgeon (32). This was in contrast to patients who selected 
mastectomy with or without reconstruction, where fear of can-
cer and concern about radiation therapy were ranked as more 
significant factors.
One of the major goals for providers is to help patients make 
informed decisions about their care. The development and use of 
decision-making aids have been investigated by several groups as 
a way to help providers obtain a better understanding of patient 
preferences for treatment (33, 34). These aids may also enhance 
patient decision-making by improving delivery of information 
and facilitating communication between providers and patients. 
In one study, patients and surgeons were interviewed to identify 
key factors influencing breast cancer surgery decisions, which 
were then incorporated into a decision board that could be 
reviewed at the time of surgical consultation (34). For patients, 
information on options for reconstruction, quality of life, and 
body image was important factors, whereas for surgeons, details 
regarding treatment side effects were considered important. 
The decision board was administered to 175 patients and 98% 
reported that it was easy to understand and 81% indicated that it 
helped in the decision process. Surgeons also found the decision 
board to be helpful in presenting information to patients. A sub-
sequent randomized trial comparing the decision board to usual 
care demonstrated that patients who had surgical consultations 
with the decision board had higher knowledge scores regarding 
treatment options (66.9 vs. 58.7, P  <  0.0001), less decisional 
conflict (1.40 vs. 1.62, P =  0.02), and were more satisfied with 
the decision-making process (4.50 vs. 4.32, P = 0.05). In addi-
tion, patients in the decision board group were more likely to 
undergo BCS (94 vs. 76%, P = 0.03). A similar approach using an 
interactive CD-ROM decision aid showed that patients using the 
CD-ROM were more satisfied with the amount of information 
received, their treatment decisions, and the decision-making 
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process (33). However, the CD-ROM decision aid had no impact 
on treatment decisions. A recent meta-analysis of studies using 
decision aids in breast cancer patients, which included the above 
studies, demonstrated that in the three randomized trials of 
decision aids, women were 25% more likely to choose BCS over 
mastectomy if a decision aid was utilized (risk ratio 1.25, 95% 
CI 1.11–1.40) (35). In addition, decision aids increased patient 
knowledge by 24%, decreased decisional conflict, and improved 
the overall decision-making process.
BODY iMAGe AND BReAST 
ReCONSTRUCTiON
An important concern for women undergoing breast cancer 
surgery is the impact this will have on body image and sexuality. 
Some studies have demonstrated that women undergoing BCS 
have fewer concerns about body image compared to mastec-
tomy patients (36–39), whereas others have found no difference 
between the BCS and mastectomy groups (40, 41). In a recent 
meta-analysis of 12 studies on body image after breast cancer 
surgery, Fang et al. demonstrated that BCS patients had a better 
overall body image than women undergoing mastectomy with 
reconstruction and scored higher on body stigma domain (42). 
However, reconstruction significantly improved body image in 
mastectomy patients compared to no reconstruction. In addition, 
cosmetic satisfaction in postmastectomy patients with recon-
struction appears to be high (43, 44). Currently, in the United 
States, universal coverage for postmastectomy reconstruction 
is mandated based on the passing of the Women’s Health and 
Cancer Rights Act in 1998. Despite the majority of patients do 
not undergo reconstruction (19). Factors associated with not 
receiving postmastectomy reconstruction include social and 
racial disparities, including black race, lower educational level 
and income, and public insurance (45–48). Although the racial 
disparity with breast reconstruction has been shown in multiple 
studies, a review of the Department of Defense cancer database 
shows that the receipt of reconstruction between White and 
Black women was equivalent, suggesting that the racial dispar-
ity with reconstruction may not be as evident when access is 
equal (49). Other factors associated with low reconstruction 
rates include older patient age, advanced disease, presence of 
comorbidities, and lack of access to reconstructive surgeons 
(19, 45–47). Although exogenous factors influencing recon-
struction rates can be identified by institutional and database 
reviews, few studies have examined patients’ perspective of 
decision-making about breast reconstruction. In a survey study 
of breast cancer patients sampled from the SEER database, the 
majority of mastectomy patients reported satisfaction with the 
decision-making process about reconstruction. Dissatisfaction 
was associated with race, with black and Latina women being 
less satisfied, but was not associated with income or educational 
level. The most common reasons cited by patients for not under-
going reconstructive surgery are to avoid additional surgery and 
that they did not feel reconstruction was important. The main 
systems barrier reported to obtain reconstruction was lack of 
insurance coverage, whereas knowledge of the reconstruction 
as an option and finding a reconstructive surgeon were not 
significant barriers (45).
CONTRALATeRAL PROPHYLACTiC 
MASTeCTOMY
Contralateral prophylactic mastectomy (CPM) is the removal of 
the healthy breast in the treatment of a unilateral cancer. Reviews 
of large national databases in the United States have demonstrated 
an increase in the rates of CPM in cases of operable breast cancer 
by over 150% (50, 51). This trend has also been reproduced in 
multiple single institution studies, with centers reporting CPM 
rates as high as 24% in the treatment of mastectomy patients 
(52,  53). These data are notable for the finding that patient 
factors are often more powerful predictors than tumor factors. 
Specifically, White race, higher socioeconomic status, and young 
age have been consistently identified as independent predictors for 
CPM (50, 52, 53). Despite the increasing frequency of CPM in the 
treatment of breast cancer, the oncologic benefit of this procedure 
is controversial in patients who do not have a genetic predisposi-
tion in developing breast cancer. Although CPM does reduce the 
risk of developing a contralateral breast cancer significantly, the 
incidence of contralateral cancers is low and has been declining 
over time due to advances in adjuvant chemotherapy and endo-
crine therapy (54). Currently, the incidence of contralateral breast 
cancer in patients can be estimated based on large retrospective 
cohort reviews and ranges from 0.3 to 1% per year depending 
on the age of diagnosis and characteristics of the primary tumor 
(54–56). The data on survival benefit of CPM are contradictory. 
Retrospective studies comparing unilateral mastectomy with 
CPM have demonstrated disease specific and overall survival 
benefit (57, 58). However, more recent data suggest that there is 
no difference in survival when breast conservation is compared 
with CPM (59). A recent meta-analysis conducted by Cochran 
Collaboration concluded that there was insufficient evidence to 
demonstrate a survival benefit with CPM (60).
Data on patients’ motivations for choosing CPM indicate 
that the patient’s choice for CPM appears to be dominated by a 
fear of developing another breast cancer, whereas the risk of a 
contralateral breast cancer and disease-specific death is routinely 
overestimated by patients (61–64). In a prospective survey of 
newly diagnosed breast cancer patients, Abbott et al. found that 
the mean estimated risk by patients for developing a contralateral 
cancer was 31% over 10 years, about ninefold the expected risk 
of most breast cancer patients. The perceived risk was not associ-
ated with stage, family history of breast cancer, or age of diagnosis 
(61). Similarly, in a qualitative study consisting of interviews with 
mastectomy and CPM patients, Covelli et al. noted that patients 
estimated a high, almost inevitable, risk of cancer recurrence and 
contralateral breast cancer development that they translated into 
a high risk of breast cancer-related death. Patients who chose 
CPM feared developing a contralateral cancer and the prospect 
of undergoing breast cancer treatment again at some point in the 
future (64). These results are similar to survey studies demonstrat-
ing that the most common reasons women report for choosing 
CPM are to avoid the development of a contralateral cancer and 
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to improve their survival (61, 63). Other common reasons women 
choose CPM in these surveys were to achieve a symmetric cos-
metic result, to avoid future tests and breast cancer surveillance, 
and to allay concern that future screening would not identify a 
new cancer. Given the apparent discordance between patients’ 
anticipated benefits of CPM and the expected oncologic benefit 
expected, many clinicians have called for improving communica-
tion practices and patient education in this area. Currently, the 
use of decision aids is being investigated as a tool to help clinicians 
and patients navigate decision-making in CPM (63, 65).
Although breast cancers secondary to a hereditary syndrome 
are uncommon, it is important to recognize that there is a popu-
lation of women who do have a high risk of developing a con-
tralateral cancer and therefore may benefit from CPM. Women 
with a deleterious BRCA mutation can have up to a 40% risk of 
developing a contralateral breast cancer over 10 years (66–68). 
CPM may also provide a survival benefit in deleterious BRCA 
mutation carriers (66, 69). Furthermore, patients with a strong 
family history without an identifiable genetic mutation appear to 
be at increased risk of developing a contralateral cancer, depend-
ing on age of diagnosis, whether the relative had a bilateral or 
unilateral cancer, and the degree of relative with breast cancer 
(first or second degree relative) (70). Genetic testing in breast 
cancer has also expanded to include next generation cancer pan-
els in addition to testing for BRCA mutations. Panel testing may 
be appropriate for women with a strong family history without a 
BRCA mutation or those who have a family history indicative for 
more than one hereditary cancer syndrome. Unfortunately, the 
addition of expanded genetic testing is not without risk. Patients 
are more likely to test positive for a genetic variant of uncertain 
significance, which can make the decision-making process about 
prophylactic surgery even more confusing (71). Additionally, data 
on risk stratification for other mutations are often not as mature 
as the BRCA data on cancer risk, and thus even in the setting of 
a deleterious mutation, it is difficult to quote accurate risk to the 
patient. Therefore, it is important for women undergoing genetic 
testing to also be formally counseled on the significance of the 
results by a specialist trained in genetic counseling.
CONCLUSiON
Choosing between mastectomy and BCS can be a difficult decision 
involving personal preferences about body image and sexuality. 
In addition, external factors can influence this choice, including 
socioeconomic status and access to adjuvant radiation therapy, 
surveillance imaging, and reconstructive surgeons. Although 
national rates of BCS for early stage breast cancers are on the 
rise, rates of mastectomy have increased in young patients for 
reasons that are unclear. Furthermore, bilateral mastectomy has 
also become a common procedure in the treatment of a unilateral 
cancer. Most breast cancer patients are at a very low risk for devel-
oping a contralateral cancer, and yet the choice for CPM appears 
to be motivated by fear of developing a new cancer in the healthy 
breast. Although significant scientific and societal advances have 
been made in improving women’s choices for the breast cancer 
treatment, there are still deficits in the decision-making processes 
surrounding the surgical treatment of breast cancer. Further 
research is needed to define optimal patient education and shared 
decision-making practices in this area.
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